Here are 1-3 brief analogies to describe ORIC Pharmaceuticals:

• A clinical-stage Genentech, focused on developing new cancer treatments.
• An early-stage Amgen, specializing in therapies to overcome cancer drug resistance.

• ORIC-114: A potent, brain-penetrant, allosteric inhibitor of EGFR Exon20 insertion mutants being developed for non-small cell lung cancer and other solid tumors.
• ORIC-507: An orally bioavailable inhibitor of the CD73 adenosine pathway being evaluated for advanced solid tumors.
• ORIC-942: A first-in-class, orally bioavailable inhibitor of PRC2-EZH2 in development for advanced solid tumors.
• ORIC-613: A potent and selective orally bioavailable inhibitor of PLK4 currently in preclinical development for various cancers.

ORIC Pharmaceuticals (ORIC) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for patients with cancer.

As a company primarily engaged in research and development and conducting clinical trials, ORIC Pharmaceuticals does not currently have any commercialized products on the market.

Therefore, ORIC Pharmaceuticals does not have "major customers" in the traditional sense of selling products or services to other companies or individuals. Its activities are focused on advancing its pipeline of drug candidates through various stages of clinical development.

Its funding primarily comes from equity financing (investors), grants, and potential future milestone payments from collaboration or licensing agreements, rather than from product sales to customers.

• WuXi STA (subsidiary of WuXi AppTec, 2359.HK)
• WuXi Biologics (2269.HK)

Jacob Chacko, MD President, Chief Executive Officer and Board Member

Dr. Chacko has served as CEO of ORIC Pharmaceuticals since April 2018. Prior to ORIC, he was CFO of Ignyta, a Nasdaq-listed precision oncology company that was acquired by Roche in February 2018. At Ignyta, he had a broad operational role and helped raise over $500 million in capital, contributing to the company's growth to a $1.7 billion enterprise value at the time of acquisition. Before Ignyta, Dr. Chacko was an investor at TPG Capital, a global private equity firm, where he helped lead teams that completed acquisitions with an aggregate value of over $10 billion. He has also served on the board of directors of Bonti (acquired by Allergan) and EnvisionRx (acquired by Rite Aid). Dr. Chacko received his MD from UCLA and his MBA from Harvard Business School.

Dominic Piscitelli Chief Financial Officer

Mr. Piscitelli joined ORIC in September 2019. Prior to ORIC, he served as CFO of AnaptysBio, a NASDAQ-listed biotechnology company, where he helped raise over $500 million in an IPO and follow-on financings. Before AnaptysBio, he was Vice President of Finance, Strategy and Investor Relations at Medivation and played a key role in its acquisition by Pfizer. He also held roles of increasing responsibility at Astellas Pharma and OSI Pharmaceuticals, playing a significant role in OSI's acquisition by Astellas. Mr. Piscitelli began his career with KPMG and is a certified public accountant.

Pratik Multani, MD Chief Medical Officer

Dr. Multani joined ORIC in September 2018 and brings over 25 years of experience in oncology drug development and patient treatment. Most recently, he served as Chief Medical Officer of Ignyta, which was acquired by Roche, where he led all development and regulatory activities related to multiple clinical stage assets, including Ignyta's lead program entrectinib. Prior to Ignyta, Dr. Multani was Chief Medical Officer of Fate Therapeutics, and held multiple leadership positions at Kalypsys, Kanisa, and Salmedix. His biotech career started at Biogen Idec, where he was involved in the development of Zevalin and Rituxan for non-Hodgkin lymphoma.

Matthew Panuwat Chief Business Officer

Prior to joining ORIC, Mr. Panuwat was Senior Vice President of Business Development at Prothena, where he led partnership activities and established the company's global research & development collaboration with Celgene. Before Prothena, he was Head of Business Development at Medivation, where he led M&A and licensing activities.

Lori Friedman, PhD Chief Scientific Officer

Dr. Friedman joined ORIC Pharmaceuticals as Chief Scientific Officer in July 2019. She brings over 20 years of experience in cancer research, including expertise in cancer target discovery and validation, signal transduction, cancer genetics, drug discovery, pharmacology, and biomarkers. During her 15-year career at Genentech, she held roles of increasing responsibility, most recently as head of translational oncology for Genentech Research and Early Development (gRED), where her team advanced more than 20 programs into clinical development. Prior to Genentech, Dr. Friedman held various scientific leadership roles at Exelixis. She earned her PhD in molecular and cell biology from UC Berkeley and completed post-doctoral work at the University of Washington and Cambridge University.

null

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer. The company's main product candidates in its pipeline are ORIC-533, ORIC-114, and ORIC-944.

• ORIC-533: This is an orally bioavailable small molecule inhibitor of CD73, being developed for the treatment of multiple myeloma and for resistance to chemotherapy- and immunotherapy-based treatment regimens. The global revenue for ORIC-533 is expected to reach an annual total of $261 million by 2035.
• ORIC-114: This is a brain-penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency against exon 20 insertion mutations. It is being developed for non-small cell lung cancer (NSCLC) and breast and tumor-agnostic cancers. The global revenue for ORIC-114 is projected to reach an annual total of $193 million by 2035. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031, with ORIC-114 targeting specific subtypes of this cancer, including EGFR exon 20 insertions (1% to 10% of NSCLC) and HER2 mutations (2% of all NSCLC patients).
• ORIC-944: An allosteric inhibitor of the polycomb repressive complex 2 (PRC2), ORIC-944 is being developed for prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). The global prostate cancer market is anticipated to reach $29.2 billion by 2035.

1. Advancement and Potential Regulatory Approval of ORIC-114 (Enozertinib) in Non-Small Cell Lung Cancer (NSCLC): ORIC-114, a brain-penetrant EGFR inhibitor, is a lead program targeting NSCLC patients with EGFR exon 20, HER2 exon 20, and atypical EGFR mutations. The company expects to initiate Phase 3 trials for ORIC-114 in first-line NSCLC in 2026, with data from combination trials anticipated by mid-2026. Successful clinical development and eventual regulatory approval in these indications represent a significant future revenue opportunity, particularly given the unmet need for brain-penetrant therapies in NSCLC with CNS metastases.
2. Advancement and Potential Regulatory Approval of ORIC-944 in Metastatic Castration-Resistant Prostate Cancer (mCRPC): ORIC-944, an allosteric inhibitor of PRC2, is being developed in combination with androgen receptor (AR) inhibitors for mCRPC. ORIC reported promising early safety and efficacy data from its Phase 1b trial for ORIC-944 in combination with AR inhibitors. The company anticipates reporting additional combination dose escalation data in 2025 and early 2026, with the potential initiation of registrational trials in 2026. Successful progression and approval of ORIC-944 could address a critical resistance mechanism in prostate cancer, leading to substantial market penetration.
3. Strategic Collaborations and Partnerships: ORIC Pharmaceuticals has demonstrated a strategy of engaging in strategic collaborations with major pharmaceutical companies, such as Pfizer (for ORIC-533), Johnson & Johnson (for ORIC-114), and Bayer and Johnson & Johnson (for ORIC-944). These partnerships are crucial for providing funding, expertise, and potentially future co-commercialization avenues, which could translate into milestone payments, royalties, or shared profits upon successful development and launch of their drug candidates. Recent financing activities, including a private placement and ATM issuances, have extended the company's cash runway into the second half of 2028, enabling continued pipeline development.
4. Addressing High Unmet Medical Needs by Targeting Mechanisms of Therapeutic Resistance: ORIC's core mission is to develop therapies that overcome resistance in cancer, which is a major challenge in oncology and a primary cause of treatment failure. By focusing on these specific resistance mechanisms, ORIC aims to create treatments that can overcome or prevent the emergence of resistance, positioning its potential products in areas of high unmet medical need. This targeted approach, if successful, can lead to significant market opportunities and premium pricing for their therapies, ultimately driving substantial future revenue streams.

Share Issuance

• In May 2025, ORIC Pharmaceuticals completed a private placement, agreeing to sell approximately 19.2 million shares of its common stock (or pre-funded warrants) for anticipated gross proceeds of $125 million.
• The company executed a private placement in January 2024, issuing 12.5 million shares of common stock at $10.00 per share, which generated gross proceeds of $125.0 million.
• During Q2 2025 and subsequently, ORIC raised an aggregate of $117.6 million in net proceeds through at-the-market (ATM) offerings of common stock, after which the company concluded its ATM facility usage.

Inbound Investments

• ORIC Pharmaceuticals has formed strategic collaborations with major pharmaceutical companies, including Pfizer, Bayer, and Johnson & Johnson, which underscore external confidence in its research pipeline.
• In January 2025, ORIC entered into a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations.

Capital Expenditures

• Over the last 12 months, ORIC Pharmaceuticals reported approximately $1.09 million in capital expenditures.